Eysz

Executive Summary

Eysz is a Boston-based digital health company founded in 2020, developing a gamified mobile solution for objective in-office screening of absence seizures in children. Its flagship product, the Eysz HyperventilationRecorder, is FDA-registered and designed to help clinicians differentiate between Childhood Absence Epilepsy (CAE) and ADHD—a significant diagnostic challenge. The company operates at the intersection of neuroscience and ophthalmology, leveraging digital tools to address a critical unmet need in pediatric neurology. With a strong focus on improving diagnostic accuracy and reducing misdiagnosis, Eysz has the potential to become a valuable tool in clinical practice. The clinical need for Eysz's solution is substantial: absence seizures are often misdiagnosed as ADHD, leading to inappropriate treatment and delays in epilepsy management. By providing a simple, non-invasive, and engaging screening tool, Eysz aims to streamline the diagnostic process in primary care and neurology settings. The company is still in its early stages, with no disclosed funding rounds or revenue, but its FDA registration suggests progress toward commercialization. If successfully adopted, Eysz could improve outcomes for thousands of children and reduce healthcare burden. However, challenges remain in market penetration, reimbursement, and clinical validation.

Upcoming Catalysts (preview)

• TBDClinical validation study results45% success
• TBDPartnership with pediatric neurology networks40% success
• TBDSeries A funding round35% success